Modelling the hepatitis B vaccination programme in prisons. by Sutton, AJ et al.
Sutton, AJ; Gay, NJ; Edmunds, WJ; Andrews, NJ; Hope, VD; Gilbert,
RL; Piper, M; Gill, ON (2006) Modelling the hepatitis B vaccination
programme in prisons. Epidemiology and infection, 134 (2). pp. 231-
42. ISSN 0950-2688 DOI: 10.1017/S0950268805005182
Downloaded from: http://researchonline.lshtm.ac.uk/11683/
DOI: 10.1017/S0950268805005182
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Modelling the hepatitis B vaccination programme in prisons
A. J. SUTTON 1,2*, N. J. GAY 1, W. J. EDMUNDS1, N. J. ANDREWS1, V. D. HOPE3,4,
R. L. GILBERT 2, M. PIPER 5 AND O. N. GILL 2
1 Health Protection Agency, Modelling and Economics Unit, Colindale, London, UK
2 Department of Biological Sciences, University of Warwick, Coventry, UK
3 Health Protection Agency, HIV & STI Division, Colindale, London, UK
4 Centre for Research on Drugs & Health Behaviour, Imperial College, London, UK
5 Prison Health, Department of Health, London, UK
(Accepted 5 July 2005, ﬁrst published online 15 September 2005)
SUMMARY
A vaccination programme oﬀering hepatitis B (HBV) vaccine at reception into prison has been
introduced into selected prisons in England and Wales. Over the coming years it is anticipated
this vaccination programme will be extended. A model has been developed to assess the potential
impact of the programme on the vaccination coverage of prisoners, ex-prisoners, and injecting
drug users (IDUs). Under a range of coverage scenarios, the model predicts the change over
time in the vaccination status of new entrants to prison, current prisoners and IDUs in the
community. The model predicts that at baseline in 2012 57% of the IDU population will be
vaccinated with up to 72% being vaccinated depending on the vaccination scenario implemented.
These results are sensitive to the size of the IDU population in England and Wales and the
average time served by an IDU during each prison visit. IDUs that do not receive HBV vaccine
in the community are at increased risk from HBV infection. The HBV vaccination programme in
prisons is an eﬀective way of vaccinating this hard-to-reach population although vaccination
coverage on prison reception must be increased to achieve this.
INTRODUCTION
In 2002, 827 acute cases of hepatitis B (HBV) infec-
tion were reported to the Health Protection Agency
with the most frequent of the reported risk factors
being intravenous drug use [1]. The Unlinked
Anonymous Prevalence Monitoring Programme re-
ported that in 2001 61% of surveyed injecting drug
users (IDUs) were found to have been in prison [2].
In recent years the vaccination coverage of current
IDUs in the community has steadily increased from
27.9% in 1998 to 39.6% in 2001. However, more
needs to be done to vaccinate this high-risk group
and vaccination in prison oﬀers another opportunity
to achieve this.
A vaccination programme oﬀering HBV vaccine
at reception into prison began in England and Wales
in June 2001. During 2002 y13% of new receptions
at 42 prisons received HBV vaccine. This equates
to y5% of all male new receptions in prisons. With
a steady increase in vaccine coverage throughout
2003 it is anticipated that the average ﬁgure for 2003
will be 10%. Over the coming years as the programme
intensiﬁes and expands this vaccination coverage of
* Author for correspondence : Mr A. J. Sutton, Health Protection
Agency, Modelling and Economics Unit, 61 Colindale Avenue,
Colindale, London, NW9 5EQ, UK.
(Email : Andrew.Sutton@hpa.org.uk)
Epidemiol. Infect. (2006), 134, 231–242. f 2005 Cambridge University Press
doi:10.1017/S0950268805005182 Printed in the United Kingdom
initial receptions into prison is expected to continue
to increase (R. Gilbert, unpublished observations).
The current prison policy [3] for adults is to use
the super-accelerated programme with injections at
0, 7, and 21 days and a booster at the 12-month stage.
This programme is not licensed for juveniles (<18
years), and so in their case an accelerated programme
is administered at 0, 1, and 2 months with a booster
again at the 12-month stage. A person who stays in
prison for less than the time it takes to administer
three doses will not complete the vaccination pro-
gramme. Ensuring that prisoners complete the full
course of injections before they leave prison is an
ongoing problem.
Prisoners will be eligible for vaccination on each
reception into a prison that is participating in the
HBV vaccination programme. Over time persistent
oﬀenders will eventually begin returning to prison
having already received vaccination in prison. As
more persons return to prison that have been
vaccinated, less doses of vaccine will be required to
maintain vaccination coverage.
To judge the eﬀectiveness of the prison vaccination
programme, it is important to estimate how quickly
the prison and IDU populations will be vaccinated
and the maximum proportion of IDUs that can be
captured by the programme over time under diﬀerent
vaccination scenarios. To address these questions a
model is required which describes the turnover of
IDUs and non-IDUs through prison. The model can
then be used to estimate what proportion of the total
current IDU population in England and Wales will
receive HBV vaccination from alternative vaccination
scenarios over time.
The work here describes the parameterization and
sensitivity analysis of this model. The model is used to
investigate the evolution of the vaccination status
of the IDU and prison populations under a range of
scenarios describing the vaccination coverage on
prison reception.
METHODS
Population
The purpose of this paper is not to make detailed
projections regarding the prison population over time
and so in the base case we assume that both the
male prison population and the total male population
(females are not considered) of England and Wales
are stable. In the sensitivity analysis we relax this
assumption and explore how an increasing prison
population aﬀects the ﬁnal results obtained from
the model. Mortality is assumed to be zero until
74 years and inﬁnite thereafter producing a ﬁxed life
expectancy of 75 years. The model considers only
males aged 15–74 years, stratiﬁed into 60 age cohorts.
Persons enter the model at the start of the year into
the ﬁrst age cohort (at 15 years of age). Thereafter
individuals change age cohorts at the beginning of
each new year. It is assumed that the total number
of persons in each age group is the same and is con-
stant over time.
Model structure
The model describes the ﬂow of IDUs and non-IDUs
through prison. It is an age-structured determi-
nistic model based on a set of ordinary diﬀerential
equations (Appendix 1) illustrated in Figure 1 with
parameter deﬁnitions and baseline values described
in Tables 1 and 2. Each mutually exclusive compart-
ment represents a diﬀerent status of imprisonment
and injecting, and the arrows represent the ﬂow of
individuals between them. A person can either have
never been to prison, be currently in prison, or have
been previously imprisoned, and, can never have
injected drugs, be a current IDU, or have been an
IDU in the past. Prisoners are considered to be IDUs
if they were IDUs on reception into prison.
The rates of starting (b) or stopping (c) injecting
are assumed to be independent of prison status
(never, currently or previously imprisoned). The rates
at which individuals go to prison for the ﬁrst time
(m), are discharged from prison (r), and return to
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Fig. 1. Flow diagram of the age-speciﬁc turnover of
prisoners in England and Wales (including IDUs) repeated
for each of the 60 age groups. The mutually exclusive
compartments represent the diﬀerent imprisonment and
IDU states. Arrows represent the ﬂow between the states.
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prison (h) are assumed to be the same for non-IDUs
and past-IDUs but may be diﬀerent for current IDUs.
Vaccination
Throughout the model the vaccination status of
each compartment is stratiﬁed by the number of doses
received, 0, 1, 2, or 3+. The prison vaccination pro-
gramme is modelled by assuming 0, 1, 2, or 3 doses
are administered to prisoners at the beginning of their
sentence. Prison vaccine coverage (any dose) is given
by parameter a and is deﬁned as the proportion
of prisoners that receive at least one dose of HBV
vaccine on prison reception. The parameters a, b, and
c represent the proportion of those vaccinated who
receive one dose, two, or three doses of vaccine
respectively (c=1xaxb).
IDUs may be vaccinated outside prison in the
community, implemented in the model as an annual
event. It is assumed that a proportion l of IDUs
are given three doses and that this proportion is con-
stant over time, with age, and with injecting career
length. The model is run to steady state prior to the
introduction of prison vaccination.
Table 1. Baseline parameter estimates and deﬁnitions (age-speciﬁc baseline values are described in Table 2)
Symbol Deﬁnition
Baseline value (all rates :
per person/year)
b The rate that current IDUs stop injecting Age speciﬁc
c The rate that non-IDUs and past-IDUs start injecting Age speciﬁc
m The rate that non-IDUs and past-IDUs go to prison for the ﬁrst time Age speciﬁc
m* The rate that IDUs go to prison for the ﬁrst time Age speciﬁc
r The rate that non-IDUs and past-IDUs are discharged from prison Age speciﬁc
r* The rate that IDUs are discharged from prison Age speciﬁc
h The rate that non-IDUs and past-IDUs return to prison having
been previously imprisoned
Age speciﬁc
h* The rate that IDUs return to prison having been previously imprisoned Age speciﬁc
t Average injecting career length dependent on injecting starting age [4] 5.97 years
Size of the male IDU population 120 000
Size of the male prison population 61 775
Total male population Variable with age
(see ONS 2000 [12])
l The rate that IDUs are vaccinated in the community 0.106
a The proportion of prisoners that receive at least one dose of
vaccine on prison reception
Variable (see text)
a The proportion of those vaccinated that receive one dose of vaccine 0.38
b The proportion of those vaccinated that receive two doses of vaccine 0.28
c The proportion of those vaccinated that receive three doses of vaccine 0.34
Table 2. Baseline estimates for age-speciﬁc parameters
Symbol Deﬁnition
Age group (years)
15–19 20–24 25–29 30–34 35–39 40–49 50–59 60–69 70+
b Stop rates# 0.0040$ 0.0803 0.1807 0.2796 0.3139 0.3139 0.3139 0.3139 0.3139
c Start rates# 0.0030 0.0045 0.0029 0.0012 0.0005 0.0001 0.0 0.0 0.0
r Discharge rates 4.3574 1.9180 1.4258 1.2294 1.0063 0.9604 0.9604 0.9604 0.9604
r* 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539 4.5539
m First-time imprisonment 0.0042 0.0018 0.0011 0.0008 0.0006 0.0004 0.0002 0.0002 0.0001
m* rates# 0.5274 0.3144 0.2605 0.2307 0.2108 0.1905 0.1718 0.1586 0.1508
h Repeat imprisonment 1.3405 0.5778 0.2497 0.1087 0.0480 0.0163 0.0048 0.0027 0.0023
h* rates# 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805 0.4805
# Continuous functions ; parameters shown are averaged over each age group.
$ Stop rate 0 up to and including 18 years of age.
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Model parameterization
Where possible parameters were directly calculated
from speciﬁc data sources (c, b, r), otherwise were
indirectly estimated by maximum likelihood from
data on IDUs and prisons (h, m). Age-speciﬁc rates
at which IDUs start and stop using drugs [c(a) and
b(a)] were taken from analysis of the current and re-
ported starting age of injecting in IDUs in contact
with services [4].
Prison discharge rates [r(a) and rI(a)]
Data were taken from a survey of prisoners during
1997–1998 [5] describing the sentence length, the age,
and the IDU status of prisoners from a cross-section
of prisons in England and Wales. There are two
diﬃculties in calculating the average length of
imprisonment per spell of imprisonment for IDUs
and non-IDUs from these data; the actual time served
for a sentence will be less than the sentence length
imposed, and, a cross-sectional survey of prisoners’
current sentence lengths is not representative of
all admissions because the prisoners serving longer
sentences will be over-represented.
Prison statistics 2001 [6] provides data on the
average time served by length of sentence, and so data
were adjusted from length of sentence to average
time served. To allow for the over-representation of
longer sentences in the prison survey, the number
of prisoners for each length of sentence was weighted
by 1/(average time served). The discharge rate for
each age group was then calculated (Table 2).
Imprisonment rates [m(a), mI(a) h(a), and hI(a)]
The rate of ﬁrst-time imprisonment for IDUs and
non-IDUs, and the rate of repeat imprisonment for
IDUs and non-IDUs were estimated concurrently
by ﬁtting the model to data described in Figure 2 by
maximum likelihood (Appendix 2) keeping previously
estimated parameters (discharge rates, IDU start and
stop rates) at their base-case level.
Figure 2(d) shows the proportion of the male prison
population that are current IDUs [5]. The original
data for the 15–20 years age group was 1.6%
(11/708). From the UA Survey 2001 35% of IDUs
aged 15–17 years had been to prison and for the
18–20 years group the ﬁgure was even higher at 44%.
Coupled with the fact that the young oﬀender data
was only obtained from one institution, it may be
that this ﬁgure is not a true reﬂection of the pro-
portion of imprisoned young oﬀenders that are IDUs.
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Fig. 2.Model ﬁt to age-speciﬁc data for (a) the percentage of the male population that has ever been imprisoned [13] ; (b) the
percentage of the male IDU population that has ever been imprisoned (2001, n=3904) [2] ; (c) the male prison population [6]
(2001, n=61 775) ; (d) the percentage of prisoners that are current IDUs [5] (n=3447).
234 A. J. Sutton and others
Additional data of arrestees aged between 17 and 24
years that were interviewed and urine-tested for drugs
whilst on arrest in police custody suites showed that
rates of last-year use of heroin, crack and cocaine
all stood at around 20% [7]. On the basis of these
concerns an alternative arbitrary value of 14.1% was
selected (100/708) as the base case. The eﬀects of
this selection are examined in the sensitivity analysis.
The full model was ﬁtted using maximum likeli-
hood (Appendix 2). For the functions describing
the ﬁrst-time and repeat reception rates, each was
examined separately to ﬁnd an appropriate func-
tional form. An iterative process in which various
functional forms were applied and tested was used.
Resultant deviances for each test were compared, with
the functional form exhibiting the lowest deviance
being selected.
It was found as a consequence of applying the
ﬁtted model that the calculated values for the dis-
charge rates for the IDU population resulted in
lower repeat reception rates for IDUs compared to
non-IDUs across all ages. IDUs are generally more
likely to re-oﬀend than non-IDUs [8], and it was
found by assuming that the discharge rate for IDUs
was the same for all age groups (at the 15–19 years
age group rate) that a higher re-imprisonment rate
for IDUs could be achieved. An argument for this
can be made when considering data from diﬀerent
types of prison from the prison survey. Considering
data from only local prisons the average time spent
in prison for an IDU across all age groups is 3.8
months, this comparable to the 2.64 months for the
15–19 years age group IDUs. The eﬀect of this is
tested in the sensitivity analysis.
The ﬁnal ﬁtted function for the ﬁrst-time reception
rate was found to follow a gamma function, and an
exponential function for the repeat reception rate
(Table 2) as shown in Figure 3(a, b). It can be seen
that the repeat reception rate was found to be con-
stant for IDUs although the exponential function
was used during sensitivity analysis.
Prison vaccination
Data were collected from the HBV vaccination pro-
gramme in prisons from January to June 2003 (not
shown) on vaccination doses administered to prison-
ers on reception during this period. To reduce the
eﬀects of truncation only data from March and April
was considered. From this data, 38% of prisoners
received one dose, 28% received two doses, and 34%
received three doses. This is applied to the model
representing vaccination parameters a, b, and c
respectively.
Community vaccination
Data was considered from the Unlinked Anonymous
(UA) survey 2001 [2] of male IDUs (who injected in
the previous 4 weeks prior to the survey) reporting
whether they have been vaccinated against HBV
by career length. Assuming both that this data is
representative of the IDU population in the com-
munity, and that all reported vaccinations were
administered in the community, the model was
ﬁtted to the data (UA survey 2001) using maximum
likelihood (Appendix 2) (ﬁt not shown). The vacci-
nation rate of IDUs in the community (l) was
estimated to be 0.106/IDU per year.
Running the model to steady state results in a
ﬁxed value of 38.4% for the proportion of IDUs
vaccinated in the community in 2001 prior to the
introduction of the prison vaccination programme.
This compares with the 39.6% of IDUs found in
the UA survey 2001.
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Fig. 3. The calculated rates of (a) ﬁrst time imprisonment and (b) re-imprisonment for IDUs and non-IDUs with
variation in age.
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Sensitivity analysis
The sensitivity analysis presented here investigates
how the following factors aﬀect the ﬁnal results from
the model. In each case by substituting alternative
values to the baseline (Tables 1 and 2) as follows:
(1) The total assumed size of the male IDU popu-
lation inside and outside prison was chosen to be
80 000 and 160000.
(2) The average injecting career of an IDU was
assumed to be 5.3 years, 6.1 years (by changing
the age-dependent injecting start and stop rates
[4]), and 20 years (assuming an age-dependent
start rate and constant stop rate across all ages)
respectively.
(3) The percentage of imprisoned young oﬀenders
that are IDUs was assumed to be 1.6% (data, see
parameterization), 4.9, 10 and 20%.
(4) The average time an IDU spends in prison was
assumed to be 2.0, 3.0, 4.0, 5.0, and 6.0 months.
(5) The community vaccination rate (l) was assumed
to be 0.00, 0.05, 0.075, 0.12 and 0.15 respectively.
(6) To simulate the eﬀects of a growing prison
population, the ﬁrst-time and repeat reception
rates into prison for IDUs and non-IDUs across
all ages are assumed to increase by 1, 2.5, and 5%
per year.
The ﬁrst four factors that were tested during sensi-
tivity analysis were used during the concurrent calcu-
lation of ﬁrst-time and repeat reception rates, these
reception rates must be recalculated during each test
of sensitivity.
As (in the base case) the prison population size
is assumed to be constant over time, i.e. the total
receptions is equal to the total discharges, it is
important that any changes to the model maintains
this equilibrium. Thus, if for instance the percentage
of young oﬀenders that are IDUs is altered, then the
average sentence lengths (and therefore the discharge
rates) of the non-IDUs must also be adjusted.
Alongside the vaccination parameters previously
described (parameterization), the baseline vaccination
scenario (described below) will be used as an input
into the model when testing model sensitivity.
Vaccination scenarios
To test the eﬀectiveness of the HBV vaccination pro-
gramme in prisons a number of vaccination scenarios
are proposed. The total proportion of prisoners on
reception that participated in the HBV vaccination
programme across all prisons in England and Wales
during 2002 was 5%, in 2003 this ﬁgure was expected
to rise to 10% and so these values are applied to all
vaccination scenarios (Table 3). For each vaccination
scenario: the parameters are as the baseline unless
otherwise stated, the vaccination coverage on recep-
tion increases linearly between 2003 and 2006 where
appropriate, and remains constant from 2006
onwards. In some cases the proposed vaccination
scenarios are not achievable in reality (i.e. maximum
scenario), however these have been selected to assist
in drawing conclusions from the model.
RESULTS
The results presented here consider the implications
of various tests of sensitivity on the results obtained
from the model when the baseline vaccination
scenario is applied. This is followed by an examin-
ation of the potential impact of the HBV vaccination
Table 3. Summary of vaccination scenarios investigated during sensitivity analysis
Strategy 2003 2006+ Notes Extra strategy
Baseline 10% 50% a=38%; b=28%; c=34%
Up to 33% 10% 33%
Up to 66% 10% 66%
No. expansion 10% 10%
Targeting young
oﬀenders
10% 100% Only young oﬀenders are
vaccinated from 2004 onwards
Baseline+vaccination
campaign
10% 50% Pulse : all prisoners given
3 doses at the end of 2004
Regular campaign 10% 0% 0% vaccination on reception
from 2004 onwards
Pulse : (see above) at the
end of 2004, 2007 and 2010
Maximum 10% 100% c=100%
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programme in prisons depending on the vaccination
scenario implemented. In both cases the key result
that has been considered is the proportion of the IDU
population both inside and outside prison that has
received two or more doses of vaccine. For clarity
of exposition in the sensitivity analysis (excluding
that examining the community vaccination rate), it
has been assumed the IDU population is initially
completely unvaccinated.
Results – sensitivity analysis
It can be seen from the results presented in
Figure 4(a–f ) that the factors that are most important
in evaluating the success of the HBV vaccination
programme in prisons are the total IDU population
size, the average time that an IDU spends in prison
during each prison visit, the increasing reception
rate into prison over time, and the rate that IDUs
are vaccinated in the community. These are the
factors that contribute towards the greatest variation
in results obtained from the model.
Results – vaccination scenarios
The vaccination scenarios, Baseline (50% by 2006),
Up to 33% by 2006, Up to 66% by 2006 and No
Expansion, all represent the potential future of the
HBV vaccination programme in prisons. It can be
seen (Table 4) that greater vaccination coverage on
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prison reception results in an increase in the total
proportion of IDUs vaccinated (2+ doses), an
increase in the vaccination status of the prison popu-
lation (2+ doses), and an increase in the number
of IDUs appearing on prison reception that receive
at least one dose of vaccine for the ﬁrst time. How-
ever an increase in vaccination coverage on reception
also requires a greater number of vaccine doses to
administer the vaccination scenario. Figure 5 shows
the vaccination status of the IDU population with
variations in age when the Baseline and ‘Up to 66%
by 2006’ scenarios have been applied.
Assuming pessimistically that the coverage on
reception does not increase from 2004 onwards,
43.1% of the total IDU population will be vaccinated
against HBV by 2012. This is only an additional 5%
of the current IDU population being vaccinated by
the prison vaccination programme, with the majority
being captured by vaccination within the community.
Increasing the vaccination coverage up to 66% by
2006 results in 61.3% of the total IDU population
being vaccinated, an additional 22.9% of the current
IDU population being vaccinated in prison.
If from 2004 only young oﬀenders are eligible for
vaccine, and by 2006 100% of them are vaccinated
on prison reception, then by 2012 48.3% of the IDU
population will be vaccinated (2+ doses) and only
24714 IDUs will receive vaccine in prison for the
ﬁrst time during this period (Table 4). When com-
pared to the baseline it can be seen that even if 100%
of young oﬀenders are receiving vaccination on
prison reception (as is the case here), this is still less
Table 4. Summary of results obtained from model with variations in the vaccination scenario applied,
where vaccinated is assumed to be those persons receiving 2+ doses of vaccine
Vaccination scenario
Total proportion of
male prison
population vaccinated
Total proportion
of male IDU
population vaccinated Total doses
administered
Total IDUs
vaccinated for
the ﬁrst time*
By 2007 By 2012 By 2007 By 2012 By 2012 By 2012
Baseline 53.5% 66.1% 52.4% 57.2% 680 049 79 743
No Expansion 26.0% 30.0% 42.2% 43.1% 204 403 26 008
Up to 33% coverage by 2006 42.8% 53.9% 48.4% 52.1% 507 150 61 281
Up to 66% coverage by 2006 63.0% 75.6% 56.0% 61.3% 759 140 86 618
Targeting young oﬀenders 33.8% 44.6% 44.6% 48.3% 298 713 24 714
Baseline+campaign 58.8% 67.7% 53.8% 57.4% 778 096 83 000
Regular campaign 100% 38.6% 45.6% 43.3% 425 086 17 184
Up to 100%+campaign 99.0% 100.0% 69.4% 72.6% 1 231 559 120 392
* The number of IDUs who are completely unvaccinated on prison reception and subsequently receive at least one dose
of vaccine in prison.
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eﬀective than expanding the vaccination coverage
including all oﬀenders on prison reception up to
50% by 2006.
While administering the Baseline vaccination
scenario it can be seen (Table 4) that the introduction
of an additional one-oﬀ vaccination campaign in
2004 has little long-term eﬀect on the vaccinated IDU
population. By 2012 only an additional 0.2% of IDUs
would be vaccinated when compared to the Baseline
scenario, this being due to the high-turnover rate of
IDUs. The implementation of regular vaccination
scenarios (in this case every 3 years) results in a
ﬂuctuation in the proportion of IDUs and prison
populations vaccinated with high values after the
vaccination campaign followed by a steady decrease
as vaccinated persons leave the populations. This
explains the 43.3% of the IDU population and 38.6%
of the prison population being captured by vacci-
nation by 2012, a decrease from 45.6% and 100%
respectively in 2007.
Increasing the vaccination coverage of prisoners
on reception into prison up to 100% by 2006 and at
the same time administering a prison vaccination
campaign at the end of 2004 results in 72.6% of
the IDU population being vaccinated by 2012. An
additional eﬀect of this vaccination scenario is the
100% vaccinated status of the prison population.
Having 100% vaccination coverage on prison recep-
tion will result in the prison population becoming
completely vaccinated over time, the inclusion of
the vaccination campaign results in this happening
much sooner.
DISCUSSION
This paper considers the structure, design, parameter-
ization, and results obtained from a model of the
HBV vaccination programme in prisons. The ﬂow
of the IDU population through prison has been given
particular attention, as this is a major at-risk group
for HBV [9], it frequently encounters prison [5, 9],
and is a diﬃcult population to vaccinate in the com-
munity. The parameterization described here helps
to inform as to the oﬀending behaviour of IDUs
when compared to non-IDUs and their ﬂow through
prison. Over a range of vaccination scenarios the
model informs as to the eﬀectiveness of various
levels of vaccination coverage on prison reception.
The model describes what proportion of both the
IDU population and prison population will be vacci-
nated over time. As the vaccination programme
is expanded to include more prisons a greater pro-
portion of IDUs will be vaccinated.
A greater community vaccination rate results in
more IDUs presenting themselves on prison reception
having already being vaccinated. The proportion
of IDUs that are being surveyed in the community
having already been vaccinated against HBV has
risen from 1998 to 2001 (see Introduction). The base
case always assumed that the community vaccination
rate (0.106/IDU per year) is constant with time
although it is acknowledged that this assumption
could be modiﬁed if the rate that IDUs are vaccinated
does continue to rise.
The eﬀectiveness of the vaccination scenario
targeting only young oﬀenders did not compare well
with the vaccination scenarios advocating increased
vaccination coverage of all prisoners on reception.
This can be explained when considering the assump-
tions made during the model construction. It has
been assumed due to the lack of data that persons
start and stop using drugs at the same rates irrespec-
tive of prison status. Therefore, persons that are
currently imprisoned or have previously been im-
prisoned are assumed to start injecting at the same
age-speciﬁc rate as those that are not. The implication
of this is that in reality targeting young oﬀenders for
vaccination on reception into prison may lead to a
greater proportion of IDUs vaccinated in the long
term than has been presented here. This is because
oﬀenders, particularly young adults, are more likely
to turn to drug use if they are currently in prison [10]
or have previously been to prison.
The maximum vaccination scenario represents the
highest vaccination coverage of the IDU population
that can be achieved through the HBV vaccination
programme in prisons (73%, assuming constant
prison and IDU population sizes). The injectors
unreachable by this programme are those who have
not (yet) gone to prison.
The results here suggest that the eﬀect of adminis-
tering a vaccination campaign either as a ‘one-oﬀ’
or regularly in which all prisoners currently in prison
are vaccinated over a short period of time has few
long-term beneﬁts, and the focus for vaccination
should be towards capturing prisoners on reception
into prison. This is because the majority of IDUs
pass through prison so quickly (short sentence
lengths) that at the time of the vaccination campaign,
relatively few IDUs will be vaccinated.
Monitoring the HBV vaccination coverage of
IDUs in the community will inform as to the impact
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of the prison vaccination programme. This can be
compared to the results from the model to see whether
the predicted vaccinated status of the IDU population
is comparable to actual data.
This work can be taken forward to consider the
impact of the HBV vaccination programme in
prisons on the prevalence and transmission of HBV
within the IDU and non-IDU populations in England
and Wales. IDUs are not the only high-risk group
from HBV that may pass through prison, sex
workers and those that engage in risky sexual prac-
tices may also beneﬁt from a prison HBV vaccination
programme. The vaccination coverage of these high-
risk groups has not been considered although it is
acknowledged that their vaccination may help to
reduce HBV incidence in England and Wales. Finally
the model could also be adapted to assess the impact
of prison-based programmes aimed at controlling
other infectious diseases, for instance vaccination
against hepatitis A virus, or screening against tuber-
culosis.
CONCLUSION
The prison vaccination programme is an eﬀective
way of improving the HBV vaccination coverage
of the IDU population. Increased vaccination cover-
age on prison reception is preferable to a vaccination
campaign in which all prisoners are vaccinated as a
‘one-oﬀ’, as more IDUs with shorter sentence lengths
will then be captured by vaccination.
APPENDIX 1
Mathematical structure
The diﬀerential equations for the deterministic model
are as follows:
dXij
dt
=x(mi+bi)Xij,
dYij
dt
=(1xa)(Xijmi+Zijhi)
+
X3
k=0
Vjk(Xikmi+Zikhi)x(ri+bi)Yij,
dZij
dt
=Yijrix(hi+bi)Zij,
dXIij
dt
=bi(XPij+Xij)x(mi*+ci)XIij,
dYIij
dt
=(1xa) (XIijmi*+ZIijhi*)
+
X3
k=0
Vjk(XIikmi*+Zikhi*
x(ri*+ci)YIij+bi(Yij+YPij),
dZIij
dt
=bi(Zij+ZPij)+YIijri*
xZIij(hi*+ci),
dXPij
dt
=XIijcix(bi+mi)XPij,
dYPij
dt
=(1xa) (XPijmi+ZPijhi)
+
X3
k=0
Vjk(XPikmi+ZPikhi
+YIijcix(bi+ri)YPij,
dZPij
dt
=YPijri+ZIijcix(hi+bi)ZPij:
The number of individuals of age i who have received
j doses of vaccine who have never been imprisoned
and are non-IDUs (X), imprisoned non-IDUs (Y),
previously imprisoned non-IDUs (Z), never been
imprisoned IDUs (XI), imprisoned IDUs (YI), pre-
viously imprisoned IDUs (ZI), never been imprisoned
previous IDUs (XP), imprisoned previous IDUs
(YP), previously imprisoned previous IDUs (ZP).
The diﬀerent parameters determining the rates of
ﬂow between imprisonment states and IDU status
are described in Table 1.
Vaccination is implemented in the model on re-
ception into prison. A proportion a(t) of prisoners
entering prison are included in the vaccination pro-
gramme. The proportions of those who receive 1, 2,
or 3 doses are denoted by a, b, and c respectively.
The vaccination status transition matrix Vjk gives
the proportion of persons that had received k doses
before reception into prison and j doses following
reception. Where:
Vjk=
1xa 0 0 0
aa 1xa 0 0
ab aa 1xa 0
ac a(b+c) a 1
0
BB@
1
CCA:
Computer details
Numerical results were generated by a ModelMaker
version 4.0 program (ModelKinetix, Wallingford,
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Oxfordshire, UK). The system was solved using
Runge–Kutta integration of ordinary diﬀerential
equations with adaptable time steps. Simulations were
performed on a PC.
APPENDIX 2
The model was ﬁtted to the data using maximum
likelihood. As the data are binomial the saturated
likelihood and the model likelihood are:
L*=
X
i
(ai In(Pi)+bi In(1xPi)),
L=
X
i
(ai In(Mi)+bi In(1xMi)),
where ai is the observed number of positives (data) in
age group i ; bi is the observed number of negative
(data) in age group i.
Pi=
ai
ai+bi
:
Mi is the modelled proportion positive in age group i.
Deviance for each data set is :
D=2(L*x L):
The above is repeated for each independent dataset,
with the deviance for each dataset being summed to
provide an overall deviance.
Over-dispersion
Due to the size of the numerator in the prison
population size, this dominates the binomial likeli-
hood. The practical eﬀect is that the model ﬁt is also
dominated by this part of the data. Despite this
no model gave a good ﬁt to these data when using
the binomial distribution. Therefore, we introduced
an over-dispersion parameter to this part of the data
using the negative binomial distribution [11]. The
over-dispersion parameter w was chosen to ﬁx the
deviance of that part of the data equal to its degrees
of freedom.
Negative binomial maximum likelihood
Yi=observed number of positives (data) for age
group i ; mi=expected number of positives (model)
for age group i.
L=
X
i
log(C(yi+wmi))xlog(C(wmi))+wmi log
w
1+w
  
:
Saturated likelihood mi=yi.
L*=
X
i
log(C(yi+wmi)xlog(C(wyi))+wyi log
w
1+w
  
:
The deviance for each model is
D=2(L* x L):
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